Streetbeat News

NTRB

Nutriband Inc.

Industry

Biotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Open

4.24

Mkt cap

49M

Volume

43K

High

4.65

P/E Ratio

-6.27

52-wk high

9.60

Low

4.15

Div yield

N/A

52-wk low

2.22

Nutriband has received approval from the Costa Rica Ministry of Health to produce and market its mosquito repellent patch. This development could expand Nutriband's market reach and potentially increase its revenue.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:18 am

Nutriband has signed a trademark licensing agreement for Bitrex brand Denatonium Benzoate to be used as an aversive agent in its Aversa Fentanyl Abuse Deterrent Transdermal Patch. This technology aims to deter oral abuse and accidental exposure to opioid and stimulant patches.

Portfolio Pulse from Nabaparna Bhattacharya

September 20, 2024 | 10:57 am

Key stocks to watch include Ferguson Enterprises, Microsoft, Nutriband, Intel, and RF Industries. Microsoft announced a $60 billion share repurchase and a dividend increase, while Intel revealed a collaboration with AWS. RF Industries reported weak Q3 results.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 6:15 am

Nutriband has authorized a $1 million share buyback program, indicating confidence in its financial health and future prospects. This move is likely to positively impact the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:03 pm

Nutriband reported cash reserves of $6.75 million as of July 31, 2024, which will support the development and commercialization of their AVERSA Fentanyl product.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:08 am

Nutriband has received a Notice of Allowance for a US trademark covering its AVERSA abuse deterrent technology. This development is significant for the company's intellectual property portfolio and could enhance its market position.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:06 am

Nutriband has provided an update on its Aversa Fentanyl product development program, aiming to complete the scale-up of the commercial manufacturing process and move towards a single Phase 1 human abuse potential study before filing an FDA application.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:29 am

Bolt Biotherapeutics shares fell 34% after reporting a GAAP loss of 28 cents per share on $5.30 million in sales. Analysts from Guggenheim and Stifel downgraded the stock. Other stocks like AERWINS Technologies and Sintx Technologies saw significant gains, while Virpax Pharmaceuticals and Yield10 Bioscience experienced notable losses.

Portfolio Pulse from Avi Kapoor

May 15, 2024 | 5:38 pm

The article highlights significant intraday movements in health care stocks on Wednesday. Notable gainers include SINTX Technologies, T2 Biosystems, Nutriband, Bone Biologics, OptimizeRx, and Eyenovia. On the losing side, Virpax Pharmaceuticals, Aethlon Medical, Yield10 Bioscience, Bolt Biotherapeutics, Oncology Institute, and TRACON Pharma saw substantial declines.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 4:32 pm

Nutriband announced an exclusive supplier agreement with Fit For Life Group for a new product launch under one of FFL's top brands, following their engagement on April 19, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:42 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.